Dear Lorraine Saipe,
Unfortunately, you have aggressive variant of MS. Our and International experience show that 70-80% of patients may achieve stabilization or improvement after HSCT. 20-30% of patients have disease relapse or progression in 2-3 years after HSCT, but in most cases in less aggressive variant then before transplantation. Risk factors for treatment failure are diseases duration more than 5 years, progressive types of MS, EDSS more than 5.0. On the other hand, aggressive type of MS is a strict indication for HSCT. Unfortunately, we have a very big waiting list and would be able to provide your admission in the beginning of November or in January 2014. The next step is planning a convenient time for admission.
I am waiting for information from you about opportunity of admission in this period.
My the best wishes, Dr. D.Fedorenko.
The A.A. Maximov Department of Hematology and Cellular Therapy, National Pirogov Medical Surgical Center, Moscow, Russia Dr. Denis Fedorenko.
This is a non-myeloablative HSCT treatment protocol utilizing Cyclophosphamide + Rituxamab or alternatively Cyclophosphamide + Carmustine
Dr. Fedorenko is also well-published on the subject of HSCT treatment of autoimmune disorders, being involved with numerous and ongoing scientific and medical international symposiums and publications, a few such as listed here (there are many more than just these):
Based upon his publications and experience, Dr. Fedorenko has the credentials establishing him as an expert in the field of HSCT treatment for autoimmune disorders.
National Pirogov Medical Surgical Center,
|Dr. Denis Fedorenko|
Picture by: From Russia with Lisa info by George Goss
I have read your email and the attached reports.
Based on the MRI scanning, your MS seems to be pretty aggressive and I note they are going to start you on first line treatment with Avonex.
Given the rather aggressive nature of your disease as per the MRI scanning, I would be inclined to go straight to second line treatment with Tysabri or Gilenya, the new oral therapy.
You will of course need to discuss this with your neurologist.
In terms of being suitable for autologous bone marrow transplantation (stem cells) you would have to fail on one of the second line treatments before being considered.
Dr Colin Andrews